Search Results
Your search for 27 matches 3404 pages
Showing 1 - 50I’m Young and Have Advanced Neuroendocrine Carcinoma of the Rectum
Eight years ago, I was 33 years old, and my main health concern was a diagnosis of ankylosing spondylitis, a form of arthritis that causes stiff, painful joints in the spine. Having a chronic disease made me pay close attention to any changes in my health, so when I noticed blood in my stool, I...
Long-Term Risks Revealed for Older Survivors of Childhood Cancers
Survivors of childhood cancer who reach the age of 50 and beyond show continued elevated risks for premature mortality, subsequent cancers, and other chronic health conditions, according to a report published in the Journal of Clinical Oncology.1 When compared with the general population or sibling ...
LLM-Based Preoperative Patient Communications Alleviate Anxiety, Physician Workload
Researchers from the Department of Urology at Fudan University Shanghai Cancer Center evaluated artificial intelligence (AI)–assisted communications in the preoperative setting to assess its impact on patient anxiety and clinician workload. The performance of the model was assessed in a...
Long-Term Outcomes With Maintenance Rucaparib in Advanced Pancreatic Cancer With BRCA or PALB2 Pathogenic Variants
In an analysis of a single-center trial reported in a research letter in JAMA Oncology, Reiss et al identified long-term outcomes with rucaparib maintenance in patients with platinum-sensitive advanced pancreatic ductal adenocarcinoma (PDAC) with BRCA1, BRCA2, or PALB2 germline or somatic...
‘Promising’ Signal Only: ctDNA in Early Breast Cancer Not Yet Ready for Clinical Use
Despite compelling prognostic associations across multiple retrospective data sets, no interventional trial has demonstrated that acting on circulating tumor DNA testing results in early breast cancer improves patient outcomes. Clinicians should therefore proceed with caution until such evidence...
FDA Approves Vepdegestrant for ER-Positive, HER2-Negative, ESR1-Mutated Advanced Breast Cancer
On May 1, the U.S. Food and Drug Administration (FDA) approved vepdegestrant (Veppanu), a heterobifunctional protein degrader, for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized ...
Novel Therapies Improve Outcomes Across Hematologic Malignancies
In an effort to help clinicians stay current with rapidly evolving hematology-oncology literature, we are providing these concise, clinically focused summaries of important peer-reviewed studies. These summaries are intended to highlight key findings, study design, and outcomes that may inform...
What Is the Optimal Setting for T-DXd in Early Breast Cancer? Experts Debate
Trastuzumab deruxtecan (T-DXd) has claimed a large share of the HER2-positive breast cancer landscape, even finding room among tumors previously thought to be HER2-negative. The DESTINY series of trials are international studies investigating T-DXd as a potential treatment option for eligible...
Overall Survival With Addition of Relacorilant to Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer
As reported in The Lancet by Lorusso et al, the phase III ROSELLA trial has shown an improvement in overall survival with the addition of relacorilant to nab-paclitaxel in patients with platinum-resistant ovarian cancer. Relacorilant is a selective glucocorticoid receptor antagonist that acts to...
Unique Phase I NSCLC Trial Sites Decreasing in United States
The number of unique clinical trial sites in the United States with phase I studies for patients with non–small cell lung cancer (NSCLC) decreased by 44% from 2020 to 2024, showing a significant consolidation of studies to only high trial volume sites in the country, according to the results of a...
Early-Onset ICI-Related Myocarditis Linked to Increased Mortality
Early-onset of immune checkpoint inhibitor (ICI)–related myocarditis was associated with an increased risk for myocarditis fatality, according to the results of a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 (Abstract 5212). The researchers suggested...
Zoldonrasib in Patients With KRAS G12D–Mutant NSCLC Previously Treated With Chemoimmunotherapy
The investigational KRAS G12D inhibitor zoldonrasib had a favorable safety profile and induced antitumor activity in some patients with KRAS G12D–mutated non–small cell lung cancer (NSCLC) who were previously treated with chemotherapy and immunotherapy, according to preliminary findings from an...
LuPSMA-617 and Pembrolizumab in mCRPC
In an Australian phase IB to II study (PRINCE) reported in The Lancet Oncology, Sandhu et al found that the combination of lutetium-177–labeled PSMA-617 (LuPSMA-617) and pembrolizumab showed “encouraging” activity in patients with metastatic castration-resistant prostate cancer (mCRPC). As stated ...
Colorectal Cancer: Duloxetine Not Effective in Preventing Oxaliplatin-Induced Peripheral Neuropathy
The antidepressant duloxetine was unable to prevent sensory oxaliplatin-induced peripheral neuropathy more significantly than placebo in patients with colorectal cancer receiving chemotherapy, according to the results of the Alliance A221805 trial published in JCO Oncology Advances. “Since we know ...
Adebrelimab and Bevacizumab Plus Platinum Chemotherapy in Triple-Negative Breast Cancer With Brain Metastases
In a Chinese phase II study (ABC) reported in the Journal of Clinical Oncology, Li et al found that the combination of the PD-L1 inhibitor adebrelimab, bevacizumab, and cisplatin or carboplatin showed high intracranial activity and progression-free survival in patients with triple-negative breast...
Presence of ctDNA at the End of Neoadjuvant Therapy May Predict Breast Cancer Recurrence
Fragments of tumor DNA circulating in the bloodstream of patients with breast cancer may predict whether they are likely to experience relapse—especially when samples are taken after the patients have received treatments prior to surgery. Findings presented at the 15th European Breast Cancer...
ASH 2025: Myelofibrosis Roundup
For myelofibrosis, the treatment landscape is poised for change as new targets have emerged, and treatments are evolving beyond the standard Janus kinase (JAK) inhibitors. Novel therapies are being paired with the commonly used JAK inhibitor ruxolitinib, as reflected by a wealth of studies...
Myelofibrosis: Treatment Landscape Is Poised for Change
For myelofibrosis, the treatment landscape is poised for change as new targets have emerged, and treatments are evolving beyond the standard Janus kinase (JAK) inhibitors. Novel therapies are being paired with the commonly used JAK inhibitor ruxolitinib, as reflected by a wealth of studies...
AMA Survey Finds Rapid Growth in Physician AI Adoption
The 2026 Physician Survey on Augmented Intelligence from the American Medical Association’s (AMA) Center for Digital Health and AI indicates that physician adoption of AI is increasing alongside growing confidence in the technology’s ability to address clinical challenges. This annual survey on...
Neoadjuvant/Adjuvant Doublet Significantly Improved Survival in Patients With Muscle-Invasive Bladder Cancer
The combination of the NECTIN4-directed antibody drug conjugate enfortumab vedotin-ejfv and the immunotherapy drug pembrolizumab is the established first-line standard-of-care treatment for patients with locally advanced/metastatic urothelial carcinoma. The results from the randomized phase III...
SABCS 2025: High-Level Review of Select Data
The 2025 San Antonio Breast Cancer Symposium (SABCS 2025) featured some exciting presentations. The early breast cancer highlights at SABCS 2025 included the landmark lidERA trial, which explored the efficacy of the oral selective estrogen receptor degrader (SERD) giredestrant in the adjuvant...
Colorectal Cancer: ACS Report Shows Increasing Incidence, Mortality Rates in Younger Adults
Findings from the American Cancer Society's triennial report, Colorectal Cancer Statistics, 2026, show that rates of colorectal cancer are decreasing in older adults; however, rates of colorectal cancer incidence in younger adults continue to increase, with a greater proportion of these cancers...
Perioperative Enfortumab Vedotin Plus Pembrolizumab May Reduce Risk of Recurrence in Patients With Muscle-Invasive Bladder Cancer
The results from the randomized phase III KEYNOTE-B15/EV-304 study show that neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab significantly improved event-free survival, overall survival, and pathologic complete response rate in patients with muscle-invasive bladder cancer who were...
ASCO’s First Living Guideline in GU Cancers Reflects Recent Practice-Changing Trials on Systemic Treatment of mCRPC
ASCO has published an updated guideline on systemic therapy for patients with metastatic castration-resistant prostate cancer (mCRPC), representing ASCO’s first Living Guideline in the area of prostate cancer and the first in any genitourinary (GU) cancer.1 “Guidelines will become less useful if...
First Results of Phase III OLYMPIA-3: Odronextamab Plus CHOP in Untreated DLBCL
The bispecific antibody odronextamab plus standard CHOP (cyclophosphamide, vincristine, doxorubicin, prednisone) chemotherapy yielded robust and durable responses in treatment-naive patients with diffuse large B-cell lymphoma (DLBCL), based on the first results of the phase III OLYMPIA-3 study...
Induction Nivolumab Before CRT in High-Risk HPV-Driven Oropharyngeal Cancer
In a French phase II trial (IMMUNEBOOST-HPV) reported in the Journal of Clinical Oncology, Mirghani et al found that use of induction nivolumab prior to chemoradiation (CRT) did not meet the endpoint of ‘receipt of full treatment in due time’ (FTDT) in patients with high-risk human papillomavirus...
COA Survey Shows Insurer Utilization Management Interferes With Cancer Treatment Decisions
A national survey of independent community oncology practices has found that utilization management tactics imposed by health insurers and pharmacy benefit managers (PBMs) delay cancer treatment, interfere with physician-directed care, and increase administrative and financial burdens on practices...
ASH 2025: Myelofibrosis Roundup
For myelofibrosis, the treatment landscape is poised for change as new targets have emerged, and treatments are evolving beyond the standard Janus kinase (JAK) inhibitors. Novel therapies are being paired with the commonly used JAK inhibitor ruxolitinib, as reflected by a wealth of studies...
Adjuvant Aumolertinib in EGFR-Mutated NSCLC
As reported in The Lancet Oncology by Zhang et al, the Chinese phase III ARTS trial showed superior disease-free survival with the third-generation EGFR tyrosine kinase inhibitor aumolertinib as adjuvant therapy vs placebo in patients with completely resected stage II to IIIB EGFR-mutated non–small ...
Responses to Initial Pembrolizumab Support Treatment De-escalation in Cutaneous Squamous Cell Carcinoma
A response-adapted approach to treatment decision-making for patients with resectable cutaneous squamous cell carcinoma demonstrated that with the use of neoadjuvant pembrolizumab, many patients could avoid surgery and/or radiotherapy. Findings from the De-Squamate study were published in the...
Multiple Myeloma: FDA Approves Daratumumab and Hyaluronidase-fihj in Combination With VRd
On January 27, the U.S. Food and Drug Administration (FDA) approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous...
Pembrolizumab Plus Lenvatinib in Recurrent Gynecologic Clear Cell Carcinoma
In a phase II trial (LARA) reported in The Lancet Oncology, Ngoi et al found that the combination of pembrolizumab and lenvatinib was active in patients with recurrent gynecologic clear cell carcinoma. Study Details In the trial, 25 efficacy-eligible patients (27 in safety population) with at least ...
ACS Report Shows 5-Year Survival for All Cancers Combined Has Reached 70%
New data published by Siegel et al in the American Cancer Society’s (ACS) Cancer Statistics, 2026 report show that, for the first time, the 5-year survival rate for all cancers combined has reached 70% for individuals diagnosed during 2015 to 2021 in the United States. In addition, those diagnosed...
Addition of Nivolumab to Docetaxel in ARPI-Pretreated, Chemotherapy-Naive Advanced Prostate Cancer
As reported in The Lancet Oncology by Fizazi et al, the phase III CheckMate 7DX trial showed no progression-free or overall survival benefit with the addition of nivolumab to docetaxel in patients with androgen receptor pathway inhibitor (ARPI)–pretreated and chemotherapy-naive metastatic...
Triplet Therapy Demonstrates Superior Progression-Free Survival in First-Line dMMR/MSI-H Metastatic Colorectal Cancer
The combination regimen of FOLFOX chemotherapy (leucovorin, fluorouracil, and oxaliplatin), bevacizumab, and atezolizumab led to a statistically significant improvement in progression-free survival compared with atezolizumab monotherapy for the first-line treatment of patients with deficient...
P-RAD Trial Shows Increased T-Cell Infiltration With Preoperative Radiation Added to Anti–PD-1 Therapy in Early Breast Cancer
Preoperative radiation therapy added to anti–PD-1 immune checkpoint inhibition led to a significant increase in T-cell infiltration in patients with hormone receptor–positive/HER2-negative early-stage breast cancer, according to findings from the phase II P-RAD trial presented at the 2025 San...
AI Tops Density in Predicting Breast Cancer Risk
An image-only artificial intelligence (AI) model for predicting the 5-year risk of breast cancer provided stronger and more precise risk stratification than breast density assessment, according to a news statement issued about a study presented at the annual meeting of the Radiological Society of...
Neoadjuvant Dual ICI Blockade vs Perioperative FLOT in dMMR/MSI-H Gastroesophageal Adenocarcinoma
In an individual-patient pooled analysis reported in the Journal of Clinical Oncology, Raimondi et al found that neoadjuvant treatment with dual CTLA-4/PD-(L)1 immune checkpoint inhibitors (ICIs) was associated with higher pathologic response rates vs perioperative FLOT (fluorouracil, leucovorin,...
SIO 2025: The Future of Integrative Oncology
Guest Editor’s Note: In October, the Society for Integrative Oncology (SIO) held its annual international conference in Boston. The theme was “The Future of Integrative Oncology,” with presentations and workshops focused on evidence-based integrative therapies and innovative research methodologies. ...
How AI Is Ushering in a New Era in Cancer Care
On October 30, 2025, Google Cloud held its second annual Cancer AI Symposium to explore how artificial intelligence (AI) is advancing cancer research, diagnosis, and treatment, in unparalleled ways. Held at Google’s St. John’s Terminal office in New York City, the event brought together leaders in...
New FDA-Approved Oncology Drugs and Label Updates Between December 1, 2024, and November 19, 2025
Over the past year (December 2024–November 19, 2025), the U.S. Food and Drug Administration (FDA) approved and expanded indications for many drugs related to the treatment of different types of cancers. The new approvals and accelerated approvals are listed below according to the most recent new...
Final Analysis Supports Use of Durvalumab Plus BCG Infusions in High-Risk Non–Muscle-Invasive Bladder Cancer
In patients with high-risk non–muscle-invasive bladder cancer, the addition of 1 year of the PD-L1 inhibitor durvalumab to standard induction and maintenance bacillus Calmette-Guérin (BCG) infusions led to a statistically significant and clinically meaningful improvement in disease-free survival...
Nivolumab and Ipilimumab in Advanced dMMR/MSI-H Noncolorectal Cancers
In an Australian and New Zealand phase II trial (MOST-CIRCUIT) reported in JAMA Oncology, Carlino et al found that combined anti–PD-1/CTLA-4 blockade was associated with a high rate of durable responses in patients with advanced mismatch repair–deficient/microsatellite instability–high (dMMR/MSI-H) ...
Image-Only AI Model Outperforms Breast Density Assessment for 5-Year Breast Cancer Risk Stratification
An image-only artificial intelligence (AI) model demonstrated stronger and more precise risk stratification than breast density assessment for predicting 5-year risk for developing breast cancer, according to findings from a study presented at the 2025 Annual Meeting of the Radiological Society of...
No Overall Survival Benefit for Lenvatinib in LEAP-014 Trial of Esophageal Cancer
For the first-line treatment of metastatic esophageal squamous cell carcinoma, the addition of lenvatinib to pembrolizumab and chemotherapy failed to improve overall survival over pembrolizumab plus chemotherapy in the phase III LEAP-014 trial, as reported at the European Society for Medical...
How an Endowed Chair in Cord Blood Research Is Providing New Hope for Patients With High-Risk Leukemia
In 2016, Filippo Milano, MD, PhD, Associate Professor, Translational Science and Therapeutics Division, and Director of the Cord Blood Transplant Program at Fred Hutchinson Cancer Center in Seattle, published the results of his landmark study investigating whether an alternative stem cell donor...
Zanzalintinib Plus Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer
The phase III STELLAR-303 trial evaluated the anti-VEGFR–related multitargeted tyrosine kinase inhibitor zanzalintinib in combination with the PD-L1 inhibitor atezolizumab vs the multikinase inhibitor regorafenib in patients with previously treated non–microsatellite instability (MSI)–high...
Final Analysis Supports Use of Durvalumab Plus BCG Infusions in High-Risk Non–Muscle-Invasive Bladder Cancer
In patients with high-risk non–muscle-invasive bladder cancer, the addition of 1 year of the PD-L1 inhibitor durvalumab to standard induction and maintenance bacillus Calmette-Guérin (BCG) infusions led to a statistically significant and clinically meaningful improvement in disease-free survival...
Pembrolizumab Plus Weekly Paclitaxel Improves Survival Outcomes in Platinum-Resistant Recurrent Ovarian Cancer
The addition of the PD-1 inhibitor pembrolizumab to weekly paclitaxel, with or without the VEGFA-targeted bevacizumab, significantly improved progression-free survival and overall survival in patients with platinum-resistant recurrent ovarian cancer, in the randomized, double-blind, phase III...
Geriatric Assessment–Guided Approach to Treatment Intensity in Older Adults With Acute Myeloid Leukemia
“Pretreatment geriatric assessment in older adults with acute myeloid leukemia is feasible, can identify several functional impairments, and [can] guide the selection of treatment intensity,” resulting in low rates of early mortality, according to Vijaya R. Bhatt, MBBS, MS, of the University of...
